The Beta Bionics Patch Pump Could Shake Up The Industry

At this year’s ADA Scientific Sessions, Beta Bionics offered a first public look at its upcoming tubeless insulin pump, Mint. The device was previewed at an investor meeting earlier this week. Beta Bionics says it expects Mint to launch by the end of 2027—a cautious projection that suggests they’re trying to avoid the missteps that have plagued other device rollouts.

Mint is a patch-style, semi-reusable pump controlled via a mobile app (iOS and Android). It joins a small but growing category of tubeless pumps—currently dominated by Insulet’s Omnipod and, in the near future, soon-to-launch systems like Tandem’s Sigi and Medtronic’s MiniMed Fit. But Beta Bionics isn’t looking to replicate what’s already out there. The company is clearly leaning into its strength: simplifying insulin delivery workflows with minimal input from the user. Much like the original iLet pump, Mint appears to prioritize automation, seamless transitions, and quick updates over feature bloat.

3 Day Wear, 200 Units, And Some Gaps

Let’s start with the basics. Mint will offer a standard 3-day wear time with a 12-hour grace period—an improvement over Omnipod’s 8-hour grace window. That’s a modest step in the right direction, but for a product launching in late 2027, it may not be enough. Tandem’s 7-day infusion set is already under FDA review, and Medtronic has made clear its tubeless MiniMed Fit will use its current 7-day Extended Wear Infusion Set. Users are starting to expect longer wear times and by 2027, I imagine that yearning will have grown.

Subscribe to All Access to view this post.